Short answer
ANGIODYNAMICS INC (ANGO) filed an 8-K current report with the SEC on April 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Item 2.02 language only addresses regulatory treatment of the disclosure.
ANGIODYNAMICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 language only addresses regulatory treatment of the disclosure
- No operating results, financial figures, or fiscal-year performance metrics included in the provided text
Item 7.01 · Regulation FD Disclosure
- Forward-looking statements cover AngioDynamics’ strategy, financial outlook, products, growth opportunities, and operating plans
- Key risks include FDA actions, clinical-trial results, competition, healthcare reforms, litigation, recalls, and product liability
- Inflation, tariffs, labor shortages, supply-chain constraints, and capital-market conditions could affect execution and results
- Investors should rely on the accompanying presentation for substantive disclosed information and review the fiscal 2025 Form 10-K risk factors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANGIODYNAMICS INC 8-K filings
Get the next ANGO 8-K as it lands
Follow ANGO for push alerts, or ask the research agent what this filing means.